Evidence map›Paper›PMID 34118880›Full record

Observational studyBMC cardiovascular disorders2021

Feasibility and safety of cangrelor in patients with suboptimal P2Y

A Selvarajah, A H Tavenier, W L Bor, V Houben, S Rasoul, E Kaplan, K Teeuwen, S H Hofma, E Lipsic, G Amoroso and 4 more

Open access · goldAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cardiovascular disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. The role of cangrelor in acute and high-risk PCI settings.European heart journal. Cardiovascular pharmacotherapy · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

A SelvarajahDepartment of Cardiology, Isala Hospital, Zwolle, The Netherlands.
A H TavenierDepartment of Cardiology, Isala Hospital, Zwolle, The Netherlands.
W L BorDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
V HoubenDepartment of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands.
S RasoulDepartment of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands.
E KaplanDepartment of Cardiology, Venlo VieCuri Medical Center, Venlo, The Netherlands.
K TeeuwenDepartment of Cardiology, Catharina Hospital, Eindhoven, The Netherlands.
S H HofmaDepartment of Cardiology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
E LipsicDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
G AmorosoDepartment of Cardiology, OLVG Hospital, Amsterdam, The Netherlands.
M A H van LeeuwenDepartment of Cardiology, Isala Hospital, Zwolle, The Netherlands.
J M Ten BergDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
A W J van 't HofDepartment of Cardiology, Isala Hospital, Zwolle, The Netherlands.
R S HermanidesDepartment of Cardiology, Isala Hospital, Zwolle, The Netherlands. r.s.hermanides@isala.nl.
Isala · NLZuyderland Medisch Centrum · NLSt. Antonius Ziekenhuis · NLMedisch Centrum Leeuwarden · NLOLVG · NLRadboud University Nijmegen · NLUniversity Medical Center Groningen · NLVieCuri Medisch Centrum · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the advances of potent oral P2Y STUDY

designThe Cangrelor Registry is a prospective, observational, multicenter, single-arm registry with cangrelor administered pre-PCI in: (1) P2Y

Indexed as

Percutaneous Coronary InterventionResearch DesignAdenosine MonophosphateFeasibility StudiesHumansMyocardial IschemiaNetherlandsPatient SafetyPlatelet Aggregation InhibitorsProspective StudiesPurinergic P2Y Receptor AntagonistsRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeAdenosine MonophosphatecangrelorPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsCangrelorP2Y12 inhibitorsPercutaneous coronary interventionPlatelet inhibition

Identifiers

PMID34118880
PMCPMC8199523
OpenAlexW3168457675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.